Key result
Amiodarone and its metabolite desethylamiodarone concentrated highest in liver and lung tissues, with tissue levels relating more closely to total dose than to plasma concentrations.
Why the study?
What is the tissue distribution of amiodarone and its metabolite desethylamiodarone in patients receiving amiodarone therapy?
Population
6 postmortem patients who received amiodarone therapy (treatment period, 6-189 days; total dose, 4.8-127.0 g)
Design
Case_series
Follow-up
6-189 days (treatment period)
Authors
Loading...
Tissue accumulation may better inform amiodarone toxicity risk than plasma levels; case report leaves open validation for dose-guided monitoring.
Observational (n=6)
What is the tissue distribution of amiodarone and its metabolite desethylamiodarone in patients receiving amiodarone therapy?
Amiodarone and its metabolite accumulate primarily in the liver, lung, adipose tissue, and pancreas, with tissue concentrations correlating more with total dose than plasma levels, and can cause early fatal pulmonary toxicity.
Brien et al. (1987) conducted an observational in Patients receiving amiodarone therapy (n=6). Amiodarone was evaluated on Tissue distribution of amiodarone and desethylamiodarone. Amiodarone and its metabolite desethylamiodarone concentrated highest in liver and lung tissues, with tissue levels relating more closely to total dose than to plasma concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: